In cases of impaired renal function associated with hypercalcaemia and in cases where restricted sodium intake is required, e.g. congestive cardiac failure, hypertension or pre-eclamptic toxaemia, the sodium (20.4mmol / 469mg per tablet) and potassium (3.1mmol / 123mg per tablet) content of these tablets should be taken into consideration. In cases of hypercalcaemia associated with …
To provide clinical staff with guidance relating to the management of hypophosphataemia in adults. 1.1. What is hypophosphataemia? 1.1.1. The reference range for serum phosphate used in the Royal Cornwall Hospitals Trust is 0.8 – 1.5 mmol/L. 1.1.2.
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. Below is a text only representation of the Patient Information Leaflet (ePIL). The text only version may be available in large print, Braille or audio CD. For further …
Phosphate Sandoz™ is an effervescent tablet containing 1.936g of anhydrous sodium acid phosphate, and is indicated for hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis and malignancy, hypophosphataemia associated with vitamin D resistant rickets and vitamin D resistant hypophosphataemic osteomalacia.
Jan 31, 2016 · Phosphate-Sandoz is used to treat hypercalcaemia in conditions such as hyperparathyroidism, multiple myelomatosis, metastatic bone disease and rickets.
Phosphate Sandoz contains the active substance sodium acid phosphate. Phosphate Sandoz is used for the treatment of high blood calcium caused by conditions such as: • a cancer of the …
bone disease caused by the spread of cancers. Your doctor may have put you on Phosphate - Sandoz effervescent tablets for another reason. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Phosphate - Sandoz effervescent tablets …
Phosphates are predominantly an intracellular anion with low tissue levels being associated with muscle weakness which for ventilated patients may be associated with slow weaning. Moderate hypophosphataemia has been reported to occur in 2.5 to 3.1% of hospitalised patients.